These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26692391)

  • 1. Erratum to: Interaction of Paroxetine with Mitochondrial Proteins Mediates Neuroprotection.
    Steiner JP; Bachani M; Wolfson-Stofko B; Lee MH; Wang T; Li G; Li W; Strayer D; Haughey NJ; Nath A
    Neurotherapeutics; 2016 Jan; 13(1):237. PubMed ID: 26692391
    [No Abstract]   [Full Text] [Related]  

  • 2. Interaction of paroxetine with mitochondrial proteins mediates neuroprotection.
    Steiner JP; Bachani M; Wolfson-Stofko B; Lee MH; Wang T; Li G; Li W; Strayer D; Haughey NJ; Nath A
    Neurotherapeutics; 2015 Jan; 12(1):200-16. PubMed ID: 25404050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Synergistic Combination of Everolimus and Paroxetine Exerts Post-ischemic Neuroprotection In Vitro.
    Suvanish Kumar VS; Pretorius E; Rajanikant GK
    Cell Mol Neurobiol; 2018 Oct; 38(7):1383-1397. PubMed ID: 30062636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction.
    Gerö D; Szoleczky P; Suzuki K; Módis K; Oláh G; Coletta C; Szabo C
    Diabetes; 2013 Mar; 62(3):953-64. PubMed ID: 23223176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction to: Molecular mechanism of olesoxime-mediated neuroprotection through targeting α-synuclein interaction with mitochondrial VDAC.
    Rovini A; Gurnev PA; Beilina A; Queralt-Martín M; Rosencrans W; Cookson MR; Bezrukov SM; Rostovtseva TK
    Cell Mol Life Sci; 2020 Sep; 77(18):3691-3692. PubMed ID: 31919572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metoprolol-paroxetine interaction in human liver microsomes: stereoselective aspects and prediction of the in vivo interaction.
    Hemeryck A; De Vriendt CA; Belpaire FM
    Drug Metab Dispos; 2001 May; 29(5):656-63. PubMed ID: 11302931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidating the interaction of antidepressant drug paroxetine with ct-dsDNA: A comparative study by electrochemical, spectroscopic, and molecular docking approaches.
    Nimal R; Nur Unal D; Erkmen C; Kurbanoglu S; Siddiq M; Eren G; Shah A; Uslu B
    Bioelectrochemistry; 2023 Feb; 149():108285. PubMed ID: 36240548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine.
    Gassen NC; Fries GR; Zannas AS; Hartmann J; Zschocke J; Hafner K; Carrillo-Roa T; Steinbacher J; Preißinger SN; Hoeijmakers L; Knop M; Weber F; Kloiber S; Lucae S; Chrousos GP; Carell T; Ising M; Binder EB; Schmidt MV; Rüegg J; Rein T
    Sci Signal; 2015 Nov; 8(404):ra119. PubMed ID: 26602018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease.
    Chung YC; Kim SR; Jin BK
    J Immunol; 2010 Jul; 185(2):1230-7. PubMed ID: 20566832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxetine ameliorates lipopolysaccharide-induced microglia activation via differential regulation of MAPK signaling.
    Liu RP; Zou M; Wang JY; Zhu JJ; Lai JM; Zhou LL; Chen SF; Zhang X; Zhu JH
    J Neuroinflammation; 2014 Mar; 11():47. PubMed ID: 24618100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anxiolytic-like effect of paroxetine in a rat social interaction test.
    Lightowler S; Kennett GA; Williamson IJ; Blackburn TP; Tulloch IF
    Pharmacol Biochem Behav; 1994 Oct; 49(2):281-5. PubMed ID: 7824539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.
    Tsao YY; Gugger JJ
    Ann Pharmacother; 2009 Jul; 43(7):1366-9. PubMed ID: 19531695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient ischemic attack reported with paroxetine use.
    Manos GH; Wechsler SM
    Ann Pharmacother; 2004 Apr; 38(4):617-20. PubMed ID: 14966255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects.
    Agbokponto JE; Luo Z; Liu R; Liu Z; Liang M; Ding L
    Eur J Pharm Sci; 2015 Mar; 69():37-43. PubMed ID: 25559065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine.
    Stout SM; Nielsen J; Welage LS; Shea M; Brook R; Kerber K; Bleske BE
    J Clin Pharmacol; 2011 Mar; 51(3):389-96. PubMed ID: 20400652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT(1A) receptor antagonist WAY100635.
    Duxon MS; Starr KR; Upton N
    Br J Pharmacol; 2000 Aug; 130(7):1713-9. PubMed ID: 10928979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioenergetic restoration and neuroprotection after therapeutic targeting of mitoNEET: New mechanism of pioglitazone following traumatic brain injury.
    Yonutas HM; Hubbard WB; Pandya JD; Vekaria HJ; Geldenhuys WJ; Sullivan PG
    Exp Neurol; 2020 May; 327():113243. PubMed ID: 32057797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder.
    Saxena S; Brody AL; Maidment KM; Dunkin JJ; Colgan M; Alborzian S; Phelps ME; Baxter LR
    Neuropsychopharmacology; 1999 Dec; 21(6):683-93. PubMed ID: 10633474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photobiomodulation Mediates Neuroprotection against Blue Light Induced Retinal Photoreceptor Degeneration.
    Heinig N; Schumann U; Calzia D; Panfoli I; Ader M; Schmidt MHH; Funk RHW; Roehlecke C
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease.
    Meulendyke KA; Queen SE; Engle EL; Shirk EN; Liu J; Steiner JP; Nath A; Tarwater PM; Graham DR; Mankowski JL; Zink MC
    J Neurovirol; 2014 Dec; 20(6):591-602. PubMed ID: 25227932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.